Online tirzepatide doctorA first check before choosing care.

Recognise the medicine

The U.S. Food and Drug Administration is called the FDA.

At the September 2026 check, tirzepatide (Mounjaro, Zepbound) had FDA approval.

It acts like gut hormones: signals that help control appetite and blood sugar.

At that check, Mounjaro was approved for type 2 diabetes, which means trouble controlling blood sugar.

Zepbound’s approved weight care was for adults with obesity, or adults whose excess weight came with a related health problem.

Obesity is a medical term for a level of excess body weight.

The approved weight use includes changes to food and activity.

Know what the study found

People taking tirzepatide in a study called SURMOUNT-1 lost roughly 15%–21% of their weight on average after 72 weeks.

Average loss varied with the amount of medicine in each study group.

Adults in this study had no diabetes; they had either obesity or excess weight along with a related health problem.

People given shots with no medicine in them lost about 3% of their weight on average.

The medicine’s maker backed the study, which included regular visits and advice on food and activity.

Ask what progress could look like for your health.

Check how the visit works

Telehealth

Telehealth is care by video, phone or questions you answer online.

As of September 2026, federal rules did not require an office visit before tirzepatide could be prescribed.

Your state’s rules still decide what kind of visit is allowed.

The doctor still needs enough information about your health to decide whether to prescribe.

Ask what kind of visit your state allows and how the doctor will check your health.

For visits, the September 2026 check of state rules found that the doctor must be allowed to practise wherever you are at that time.

A state medical board grants doctor licences and keeps records you can read.

The records tell you if the licence is current and list any board action against that doctor.

A clean public record does not grade the doctor’s care.

Expect a real conversation

The medical-board guidance checked during September 2026 requires the doctor to gather enough health details to decide on your care.

The guidance requires a way for you to raise your questions and for the doctor to ask follow-up questions.

If an exam or tests are needed, that guidance calls for arranging them or sending you for in-person care.

If you prefer to talk in a room, an in-person clinic is another way to have your health checked.

Read past the product claim

Compounded medicine

A doctor or pharmacist prepares compounded medicine to order.

In September 2026, FDA approval did not cover these made-to-order medicines.

With compounded products, safety, quality and whether the medicine works are not checked by the FDA before sale.

The September 2026 rules allow some made-to-order medicines, with limits on copying approved products.

At the September 2026 check, tirzepatide was off the FDA’s national shortage list.

The national shortage had allowed pharmacies to make their own versions of the approved medicines.

For regular pharmacies, the September 2026 rules restrict repeatedly making a medicine that is essentially the same as a ready-made product already sold.

That copy limit has an exception if the person writing the prescription decides a change matters in a meaningful way for the named patient.

Having a prescription or paying less does not by itself make a pharmacy-made copy legal.

What keeps an approved medicine from meeting your needs? Ask what would be different in the proposed medicine and how that difference would matter to you.

Ask which rules allow that medicine to be made for you. Write down the answer beside the medicine’s exact name.

Check the pharmacy too

Find out who will make the medicine or send it: ask for that pharmacy’s name. Keep its exact name for a licence check.

Use the FDA’s state lookup to find the pharmacy’s licence record.

A licence record shows that the pharmacy has a licence, but it does not prove that it gives out medicines properly.

Ask if the pharmacy requires your prescription, and get a way to contact a pharmacist when you have questions.

Make room for what can go wrong

Label check: 26 September 2026.

Stomach problems

The Zepbound label lists nausea, or feeling sick, along with vomiting, loose stools and trouble passing stool as common side effects.

Severe stomach problems have been reported, along with kidney damage after the body loses too much water.

Ask who will answer if a new problem starts.

A family-history question

The thyroid is a small organ at the front of your neck.

Both tirzepatide labels warn about unusual thyroid growths seen in rats, using a boxed warning—the strongest type the FDA gives.

Whether the drug causes these growths in people is unknown.

At the label check, tirzepatide was ruled out for anyone who had medullary thyroid cancer or had a family member with it.

This is a rare cancer of the thyroid.

A previous serious allergy to tirzepatide also rules it out under the labels, as does the rare inherited condition MEN 2.

Bring plans into the visit

For a time after starting tirzepatide or raising the amount taken, birth control pills may be less effective, the Zepbound label warns.

Ask about pregnancy plans, birth control choices and any upcoming surgery.

The labels also warn about stomach contents entering the lungs during surgery with drugs that put you to sleep.

For urgent trouble

MedlinePlus says severe allergic reactions are emergencies that put lives at risk.

Get emergency help for severe breathing trouble or swelling of the tongue.